Insights on the interaction mechanism of brigatinib to human α-1-acid glycoprotein: Experimental and computational approaches

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al. · Science Translational Medicine · 2011 · 3.6K citations · Full text

Medicine, Genetics, Oncology +17

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2018 · 976 citations · Full text

Medicine, Oncology, Pharmacology +13

Principles of fluorescence spectroscopy

Fernanda Ricchelli · Journal of Photochemistry and Photobiology B Biology · 1989 · 621 citations

Natural Sciences, Biophysics, Physics +12

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

Ken Uchibori, Naohiko Inase, Mitsugu Araki et al. · Nature Communications · 2017 · 410 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 404 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13